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Identification of HnRNP-A2/B1 as a Target Antigen
of Anti-Endothelial Cell IgA Antibody in Behc¸et’s
Disease
Sung Bin Cho1, Keun Jae Ahn2, Do Hee Kim3, Zhenlong Zheng1, Suhyun Cho1, Shin-Wook Kang3,
Ju Hee Lee1, Yong-Beom Park4, Kwang Hoon Lee1 and Dongsik Bang1
Behc¸et’s disease (BD) is a chronic, multisystemic vasculitis that theoretically affects all sizes and types of blood
vessels. Although pathogenesis remains enigmatic, endothelial cells are believed to be the primary target in this
disease. We detected the target protein using western blotting and immunoprecipitation and determined the
amino-acid sequence of the peptide by liquid chromatography-matrix assisted laser desorption/ionization-
tandem time-of-flight analysis (LC-MALDI-TOF/TOF). Serum reactivity against the recombinant target protein
was analyzed by immunoblotting. Serum reactivity against streptococcal 65-kD heat shock protein (hsp-65) and
the recombinant target protein was investigated by ELISA. The 36–40-kD protein band that was obtained from
immunoprecipitation, which was analyzed by LC-MALDI-TOF/TOF, exhibited the amino-acid sequences of
heterogeneous nuclear ribonucleoproteins A2/B1 (hnRNP-A2/B1). Reactivity of serum IgA against human
recombinant hnRNP-A2/B1 was detected in 25 of 30 BD patients (83.3%), 4 of 30 systemic lupus erythematosus
patients (13.3%), 8 of 30 rheumatoid arthritis patients (26.7%), 9 of 30 Takayasu’s arteritis patients (30%), 6 of 30
healthy controls (20%), and none of 30 IgA nephropathy patients. Optical densities obtained from ELISAs against
the recombinant human hnRNP-A2/B1 were correlated with those against the recombinant streptococcal hsp-65.
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INTRODUCTION
Behc¸et’s disease (BD) is a chronic, multisystemic vasculitis
that theoretically affects all sizes and types of blood vessels
(Sakane et al., 1999; Kalayciyan and Zouboulis, 2007).
Although pathogenesis remains enigmatic, endothelial cells
are believed to be the primary target in this disease,
presenting with various symptoms of vasculitis and/or
thrombosis (Kalayciyan and Zouboulis, 2007). Histopatholo-
gical features of BD mainly consist of perivascular mono-
nuclear cell infiltration, endothelial cell swelling or necrosis,
obliteration of the vessel lumen, and fibrinoid necrosis of
vessels (Sakane et al., 1999).
Anti-endothelial cell antibodies have been found in serum
samples of individuals with various diseases including
systemic lupus erythematosus (SLE), rheumatoid arthritis
(RA), mixed connective tissue disease, systemic sclerosis,
dermatomyositis, Kawasaki disease, and IgA nephropathy
(IgAN) (Aydı`ntug et al., 1993; Wang et al., 1993; Cervera
et al., 1994; Fornasieri et al., 1995; Lee et al., 1999). Anti-
endothelial cell antibody has also been detected in serum
samples from BD patients and has proven to be associated
with disease activity and vasculitis symptoms (Aydı`ntug et al.,
1993; Cervera et al., 1994; Lee et al., 1999). By using
proteomic techniques, including matrix-assisted laser deso-
rption/ionization-time-of-flight (MALDI-TOF) mass spectrome-
try (MS), a-enolase was identified as a target antigen of IgM-
type anti-endothelial cell antibody in BD patients (Lee et al.,
2003, 2009). However, the pathogenetic role of anti-a-enolase
antibody in BD has not been fully elucidated, and several
studies have shown an association between antibodies against
a-enolase and various inflammatory and immune disorders
(Pratesi et al., 2000; Lee et al., 2003, 2009; Nahm et al., 2006).
The role of streptococci in BD immunopathogenesis has
been demonstrated in several reports (The Behc¸et’s Disease
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Research Committee of Japan, 1989; Isogai et al., 1990;
Yokota et al., 1995; Kaneko et al., 2008). BD patients have
significantly more Streptococcus sanguis as oral bacterial flora
than healthy and other disease controls (Isogai et al., 1990;
Yokota et al., 1995). BD patients show strong delayed
cutaneous hypersensitivity reactions and oral aphthous ulcera-
tions against streptococcal antigens by skin injection or oral
prick with streptococcal antigens (The Behc¸et’s Disease
Research Committee of Japan, 1989). Previously, we reported
that sera from BD patients that react with recombinant human
a-enolase also crossreact with a S. sanguis antigen, which was
determined to be streptococcal a-enolase (Lee et al., 2005;
Cho et al., 2010). S. sanguis, viridans group streptococci,
mainly inhabit the mucous membrane of the mouth, throat,
colon, and female genital tract. IgA presents in large quantity
at mucosal sites and is responsible for mucosal immunity. A
previous report revealed that BD patients who were infected
with IgA protease–producing S. sanguis strains also developed
increased IgA titers against these strains, as well as against the
IgA protease antigen (Yokota and Oguma, 1997).
The aim of our study was to identify the anti-endothelial
cell IgA antibody–binding human dermal microvascular
endothelial cell (HDMEC) antigen. We detected a target
protein using western blotting and immunoprecipitation and
then searched for a similar protein following amino acid
sequencing by liquid chromatography-MALDI-tandem time-
of-flight (LC-MALDI-TOF/TOF) analysis. We investigated the
serum reactivity of the recombinant target protein in BD,
other rheumatic diseases, and IgAN. In addition, serum IgA
reactivity against streptococcal 65-kD heat shock protein
(hsp-65) was investigated by ELISA.
RESULTS
Human heterogeneous nuclear ribonucleoprotein
(hnRNP)-A2/B1 is identified as a target protein of serum
anti-endothelial cell IgA antibody in BD patients
ELISA of extracts of HDMECs with serum samples from 30 BD
patients was performed (Figure 1a), followed by western
blotting of extracts of HDMECs with selected serum samples
from 10 BD patients presenting relatively high optical density
values on ELISA. A band of HDMEC protein between 36 and
40 kD was detected in all 10 patients (Figure 1b), but not in
normal controls or in patients with other rheumatic diseases.
Immunoprecipitation also revealed a 36–40-kD protein band
of HDMEC antigen reacting with IgA antibodies from BD
patients (Figure 1c).
The 36–40-kD protein band obtained by immunoprecipi-
tation was excised from a polyacrylamide gel and digested
with trypsin; the resulting peptide fragments were analyzed
by LC-MALDI-TOF/TOF, and a peptide fingerprint was
obtained. Using the National Center for Biotechnology
Information (NCBI) scanning algorithm, the protein band
showed the amino-acid sequences of hnRNP-A2/B1 isoform
B1 (estimated molecular weight (Mr)/pI, 37464/8.97; NCBI
accession number, gi|14043072; Swiss-Prot accession num-
ber, NP_112533; Mascot score, 56; sequence coverage, 4%).
Expression and purification of recombinant human
hnRNP-A2/B1
Human hnRNP-A2/B1 was overexpressed in E. coli BL21,
followed by purification of recombinant proteins to apparent
homogeneity using Ni-NTA resin. The purified proteins were
analyzed on a 10% SDS-PAGE at various steps during the
procedure, and the resulting protein bands were stained with
Coomassie brilliant blue R250 (data not shown). Purified
recombinant human hnRNP-A2/B1 was confirmed by wes-
tern blotting using mouse anti-human hnRNP-A2/B1 mono-
clonal antibody (data not shown).
Reactivity of BD sera with recombinant human hnRNP-A2/B1
Western blotting with recombinant human hnRNP-A2/B1
was performed to evaluate serum reactivity using sera from
patients with BD, SLE, RA, Takayasu’s arteritis (TA), IgAN,
and healthy controls. Reactivity of serum IgA against human
recombinant hnRNP-A2/B1 was detected in 25 of 30 BD
patients (83.3%), 4 of 30 SLE patients (13.3%), 8 of 30 RA
patients (26.7%), 9 of 30 TA patients (30%), and 6 of 30
healthy controls (20%) by western blot, whereas none of 30
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Figure 1. ELISA, western blotting, and immunoprecipitation using human dermal microvascular endothelial cell (HDMEC) antigen. (a) Serum samples
from 10 Behc¸et’s disease (BD) patients, presenting relatively high optical density values on ELISA of extracts of HDMECs with serum samples from 30 BD
patients, were selected (above the bar). (b) Western blotting using extracts of HDMECs with selected serum samples of 10 BD patients presented a band of
HDMEC protein between 36 and 40 kD in all 10 patients but not in normal controls or patients with other rheumatic diseases. (c) Immunoprecipitation was
performed to identify the anti-endothelial cell IgA antibody–binding antigen and revealed a 36–40 kD protein band of HDMEC antigen reacting with IgA
antibodies of BD patients.
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IgAN patients presented reactivity against recombinant
human hnRNP-A2/B1 (Figure 2). The reactivity of serum IgA
against human recombinant hnRNP-A2/B1 was significantly
higher than in healthy controls (Po0.0001) and in SLE
patients (Po0.0001), RA patients (Po0.0001), TA patients
(Po0.0001), and IgAN patients (Po0.0001). There were no
statistically significant differences in serum IgA reactivity in
SLE, RA, TA, or IgAN patients compared with healthy controls
(P40.05, respectively).
In addition, western blotting with recombinant human
a-Synuclein as a recombinant protein control was performed
to evaluate serum reactivity using the patients’ sera (Figure 3).
Reactivity of serum IgA against human recombinant
a-Synuclein was detected in 5 of 30 BD patients (16.7%), 9
of 30 SLE patients (30%), 6 of 30 RA patients (20%), 3 of 30
TA patients (10%), 1 of IgAN patients (3.3%), and 4 of 30
healthy controls (13.3%) by western blot. There was no
statistically significant difference in serum IgA reactivity
among BD, SLE, RA, TA, and IgAN patients as compared with
healthy controls (P40.05).
Serum IgA reactivity against recombinant human hnRNP-A2/B1
and recombinant streptococcal hsp-65 are correlated
Median optical density with interquartile range obtained from
ELISAs against recombinant human hnRNP-A2/B1, strepto-
coccal hsp-65, and human a-Synuclein is summarized in
Table 1. Optical densities obtained from ELISAs against the
recombinant human hnRNP-A2/B1 were correlated with
those against the recombinant streptococcal hsp-65 in
healthy controls (r¼0.738, Po0.0001), BD (r¼0.549,
P¼0.002), and SLE (r¼0.742, Po0.0001), but not in RA,
TA, and IgAN patients (Figure 4). However, optical densities
obtained from ELISA against the recombinant human hnRNP-
A2/B1 in all groups did not correlate with those against the
recombinant human a-Synuclein (P40.05).
The reactivity of serum IgA against recombinant human
hnRNP-A2/B1 was reduced in BD patients’ sera pre-
incubated with 0.5 mg (Po0.0001) and 2 mg (Po0.0001) of
recombinant streptococcal hsp-65 in a dose-dependent
manner by western blot analysis (Figure 5), but not with BD
patients’ sera pre-incubated with 0.5 mg (P40.05) and 2 mg
(P40.05) of recombinant human a-Synuclein (Figure 5).
Clinical significance of anti-hnRNP-A2/B1 IgA antibodies in BD
patients
Among the 30 BD patients, 25 patients (8 men and 17 women,
mean age 39.8±12.1) showed positive reactivity with recombi-
nant human hnRNP-A2/B1 and 5 patients (one man and four
women, mean age 46±6.1) showed negative reactivity. In BD
patients with positive reactivity for recombinant human hnRNP-
A2/B1, the following symptoms were observed in descending
order of frequency: recurrent oral ulcers in 25 patients (100%),
genital ulcers in 21 (84%), skin lesions in 21 (84%), ocular
involvement in 16 (64%), articular involvement in 9 (36%),
gastrointestinal lesions in 4 (16%), vascular involvement in 2 (8%),
central nervous system involvement in 1 (4%), and epididymitis in
1 (4%). A positive HLA-B51 test was noted in 9 patients (36%) of
the 25 patients with positive anti-hnRNP-A2/B1 IgA antibody.
In BD patients with negative reactivity for recombinant
human hnRNP-A2/B1, BD-related symptoms were observed
as follows: recurrent oral ulcers and genital ulcers in all five
patients (100%), skin lesions in four (80%), articular
involvement in four (80%), ocular involvement in two
(40%), and gastrointestinal lesions in two (40%). Vascular
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Figure 2. Western blotting using recombinant human heterogeneous nuclear
ribonucleoprotein (hnRNP)-A2/B1. Western blotting using recombinant
human hnRNP-A2/B1 was performed with sera from patients with Behc¸et’s
disease (BD), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA),
Takayasu’s arteritis (TA), IgA nephropathy (IgAN), and from healthy controls
(HC) as a primary antibody and goat anti-human IgA antibody as a secondary
antibody. Reactivity of serum IgA against human recombinant hnRNP-A2/B1
was detected in (a, b) 83.3% of BD patients, (b) 13.3% of SLE patients, (c)
26.7% of RA patients, (c) 30% of TA patients, and (a) 20% of healthy controls
on western blots, whereas (c) none of the 30 IgAN patients presented
reactivity against recombinant human hnRNP-A2/B1.
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Figure 3. Western blotting using recombinant human a-Synuclein as
recombinant protein control. Western blotting using recombinant human
a-Synuclein was performed with sera from patients with Behc¸et’s disease
(BD), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA),
Takayasu’s arteritis (TA), IgA nephropathy (IgAN), and from healthy controls
(HC) as a primary antibody and goat anti-human IgA antibody as a secondary
antibody. Reactivity of serum IgA against human recombinant a-Synuclein
was detected in (a, b) 16.7% of BD patients, (b) 30% of SLE patients, (c) 20%
of RA patients, (c) 10% of TA patients, (c) 3.3% of IgAN patients, and
(a) 13.3% of the healthy controls on western blots.
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involvement, central nervous system involvement, and
epididymitis were not observed in any of the patients. A
positive HLA-B51 test was noted in one patient (20%) of five
patients with negative anti-hnRNP-A2/B1 IgA antibodies.
There were no significant differences in any clinical
features of BD between the anti-hnRNP-A2/B1 antibody-
positive and -negative groups. Furthermore, the results of
laboratory tests, including full blood count, blood glucose,
renal and liver function tests, HLA-B51 genotyping, erythro-
cyte sedimentation rate, C-reactive protein, anti-streptolysin
O titer, rheumatoid factor, antinuclear antibodies, and
venereal disease were all similar between the anti-hnRNP-
A2/B1 IgA antibody-positive and -negative groups.
DISCUSSION
Rheumatic autoimmune diseases, including SLE, RA, mixed
connective tissue disease, systemic sclerosis, and polymyo-
sitis, characteristically present autoantibodies against intra-
cellular antigens (Kavanaugh et al., 2000). Some specific
antinuclear antibodies possess diagnostic significance, such
as autoantibodies to double-stranded DNA or Smith antigen
in SLE, autoantibodies to topoisomerase in progressive
systemic sclerosis, or autoantibodies to transfer RNA synthe-
tases in poly- or dermatomyositis (Kavanaugh et al., 2000;
Solomon et al., 2002). In contrast to these disorders,
pathognomonic autoantibodies to intracellular antigens have
not yet been defined in BD.
Table 1. The median optical densities of ELISAs for autoantibodies against recombinant proteins
Median optical density1 Correlation value (r)
Group
Human
hnRNP-A2/B1
Streptococcal
hsp-65 a-Synuclein
hnRNP-A2/B1
and hsp-65
hnRNP-A2/B1
and a-Synuclein
Healthy controls (N=30) 0.180 (0.129–0.248) 0.131 (0.077–0.195) 0.163 (0.019–0.344) 0.7382 0.142
BD patients (N=30) 0.269 (0.226–0.396) 0.202 (0.156–0.310) 0.169 (0.146–0.273) 0.5493 0.033
SLE patients (N=30) 0.269 (0.219–0.356) 0.135 (0.106–0.196) 0.296 (0.183–0.412) 0.7422 0.183
RA patients (N=30) 0.142 (0.101–0.200) 0.110 (0.064–0.172) 0.157 (0.118–0.220) 0.303 0.234
TA patients (N=30) 0.331 (0.222–0.465) 0.125 (0.076–0.183) 0.154 (0.134–0.199) 0.353 0.096
IgAN patients (N=30) 0.222 (0.141–0.308) 0.131 (0.095–0.198) 0.116 (0.075–0.201) 0.165 0.030
Abbreviations: BD, Behc¸et’s disease; hnRNP-A2/B1, heterogeneous nuclear ribonucleoprotein-A2/B1; hsp-65, 65-kD heat shock protein; IgAN, IgA
nephropathy; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TA, Takayasu’s arteritis.
1Median optical density was presented as the median (interquartile range).
2Po0.0001.
3P=0.002.
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Figure 4. Correlation of ELISA using recombinant proteins. Optical densities (ODs) obtained from ELISAs against recombinant human heterogeneous
nuclear ribonucleoprotein (hnRNP)-A2/B1 were significantly correlated with those against recombinant streptococcal streptococcal 65-kD heat shock
protein (hsp-65) in (a) healthy controls (HC; r¼0.738, Po0.0001), (b) Behc¸et’s disease (BD; r¼0.549, P¼ 0.002), and (c) systemic lupus erythematosus
(SLE; r¼0.742, Po0.0001), but not in (d) rheumatoid arthritis (RA), (e) Takayasu’s arteritis (TA), or (f) IgA nephropathy (IgAN) patients. (b)Ten BD sera
samples with relatively high OD values on ELISA of extracts of HDMECs are presented as triangle. Trend lines were analyzed by linear regression with
95% confidence intervals (dotted lines) using the GraphPad Prism software.
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HnRNPs are RNA-binding proteins and can remain with
mRNAs until their degradation in the cytoplasm. They
participate in the maturation of pre-mRNAs, the nuclear to
cytoplasmic transportation of mRNA, and mRNA localiza-
tion, translation, and stability (Dreyfuss et al., 2002; Huguet
et al., 2004). The hnRNP proteins are also involved in various
nuclear events, such as transcriptional regulation, telomere-
length maintenance, immunoglobulin gene recombination,
splicing, pre-ribosomal-RNA processing, and 30-end proces-
sing (Dreyfuss et al., 2002). Among the B30 diverse hnRNP
proteins, the hnRNP-A/B protein forms a subgroup of closely
related proteins. An hnRNP-B1 protein is a splicing variant of
hnRNP-A2 and differs from hnRNP-A2 by a 12-amino-acid
insertion close to the N terminus (Steiner et al., 1996; Wu
et al., 2003).
HnRNP-A2/B1 overexpression has been described in many
cancers, including breast, pancreas, liver, gastrointestinal, and
lung cancers (Wu et al., 2003; Tauler et al., 2010). Previous
reports suggested that hnRNP-A2/B1 is a marker for early lung
cancer (Zhou et al., 2001; Wu et al., 2003). Expression of the
hnRNP-A2/B1 may have a role in the regulation of funda-
mental cancer biology, such as migration and aerobic
glycolysis (Moran-Jones et al., 2009; Clower et al., 2010), as
well as in epithelial-to-mesenchymal transition in none-
pithelial lung cancer cell lines through the regulation of
E-cadherin expression (Tauler et al., 2010). However, a critical
role for overexpressed hnRNP-A2/B1 in the development or
progression of cancers has not been fully elucidated.
T-cell–driven autoantibody responses in rheumatic dis-
eases, including SLE and mixed connective tissue disease,
target a spliceosomal complex, which is mainly composed
of small nuclear RNPs (Jurica and Moore, 2003). In addition
to small nuclear RNPs, some hnRNPs have also been
identified as antigenic targets of rheumatic diseases, and
serum reactivities against hnRNP-A2/B1 have been described
in 30–40% of RA patients, 30–40% of mixed connective
tissue disease patients, and 20% of SLE patients (Hassfeld
et al., 1995; Steiner et al., 1996; Caporali et al., 2005). In this
study, we demonstrated an hnRNP-A2/B1 protein as a target
protein of serum anti-endothelial cell IgA antibody in BD
patients. Reactivity of serum IgA against human recombinant
hnRNP-A2/B1 was detected in 83.3% of BD patients,
whereas it was detected in 0–30% of healthy and disease
controls. In particular, none of the IgAN patients presented
reactivity against recombinant human hnRNP-A2/B1 in our
study. We think that the different target antigens reacting
with circulating IgA in BD and IgAN may contribute to the
development of different end-organ damage. In addition, we
demonstrated that the sera from BD as well as healthy and
diseased controls had 3.3–30% reactivity of serum IgA
against recombinant human a-Synuclein, which has been
suggested as a target antigen in patients with Parkinson’s
disease, as a recombinant protein control (Papachroni et al.,
2007).
We also demonstrated that serum IgA reactivity against
recombinant human hnRNP-A2/B1 and recombinant strepto-
coccal hsp-65 was significantly correlated. The hsp-65,
derived from oral bacteria including S. sanguis, can be
detected in the sera and lesions of BD patients and shows
considerable homology with peptides of the human hsp-60
(Hasan et al., 1996; Kibaroglu et al., 2004; Kaneko et al.,
2008). The crossreactivity of the antibodies in sera from BD
patients with S. sanguis and some recombinant peptides of
hsp-65 derived from S. sanguis has been demonstrated (Isogai
et al., 2002). In addition, the serum levels of IgA antibodies to
mycobacterial hsp-65, which crossreacts with selected strains
of S. sanguis, are increased significantly in BD patients
(Pervin et al., 1993; Kaneko et al., 2008), although the
corresponding parallel T-cell response to specific autoantigen
rather than the serum level of autoantibody itself has a major
role in driving the disease process in cancer immunity and in
some aspects of autoimmune processes.
It is widely accepted that certain environmental triggering
factors, such as pollutants, UV light, or infectious agents,
have important roles in the pathogenesis of BD in genetically
predisposed individuals (Sakane et al., 1999; Kalayciyan and
Zouboulis, 2007; Kaneko et al., 2008). Autoreactive T and B
cells are present in the normal mature immune system and
can escape from normal immune regulation by the triggering
factors, resulting in immune-mediated end-organ damage.
The activation of autoreactive lymphocytes can be influenced
by innate immune receptors such as Toll-like receptors,
which primarily recognize pathogen-derived molecular
structures but may crossreact with host molecules, particu-
larly nucleic acids. Varying degrees of tissue damage through
autoantibodies, direct attack of tissues by autoreactive T cells,
and cytokine production may lead to more release of self-
antigens (Frisoni et al., 2005).
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Figure 5. Cross-immunoabsorption against recombinant human
heterogeneous nuclear ribonucleoprotein (hnRNP)-A2/B1 and recombinant
streptococcal 65-kD heat shock protein (hsp-65). (a) Western blotting using
recombinant human hnRNP-A2/B1 was performed using Behc¸et’s disease
(BD) patients’ sera preincubated with 0.5 and 2 mg of recombinant
streptococcal hsp-65, as well as 0.5 and 2 mg of recombinant human
a-Synuclein. (b) Serum IgA reactivity against recombinant human
hnRNP-A2/B1 was notably reduced in BD patients’ sera preincubated with
0.5 and 2 mg of recombinant streptococcal hsp-65 in a dose-dependent
manner. (c) Significant cross-immunoabsorption was not observed in BD
patients’ sera preincubated with 0.5 mg (P40.05) and 2 mg (P40.05) of
recombinant human a-Synuclein. *P¼0.046; **Po0.0001.
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In this study, we demonstrated that an hnRNP-A2/B1
protein is a target protein of serum anti-endothelial cell IgA
antibody in BD patients. In addition, we detected that serum
IgA reactivity against recombinant human hnRNP-A2/B1 was
correlated with reactivity against recombinant streptococcal
hsp-65. Although we cannot describe a precise pathogenetic
role for hnRNP-A2/B1 or for the presence of the anti-hnRNP-
A2/B1 antibody, we suggest that an infectious triggering
factor, especially S. sanguis, activates autoreactive lympho-
cytes, which recognize streptococcal hsp-65 and then may
crossreact with human hnRNP-A2/B1. However, further
investigations are necessary to elucidate the roles of
hnRNP-A2/B1 and circulating IgA autoantibodies in BD, as
well as to determine the diagnostic value of anti-recombinant
human hnRNP-A2/B1 IgA antibody tests.
MATERIALS AND METHODS
Patients
This study was approved by the Institutional Review Board of
Severance Hospital, Yonsei University College of Medicine, Seoul,
Korea (4-2009-0744) and conducted according to the Declaration of
Helsinki Principles. This study included 30 BD patients who fulfilled
the diagnostic criteria of the International Study Group for BD
(International Study Group for Behc¸et’s Disease, 1990). All patients
had active disease, meeting at least two major criteria with or without
any number of minor criteria. Sera from 30 healthy volunteer donors,
30 patients with SLE, 30 patients with RA, 30 patients with TA, and
30 patients with IgAN were used as controls. All serum samples were
stored at 70 1C. All subjects provided written informed consent.
ELISA with HDMEC antigen
HDMECs were purchased (Lonza, Basel, Switzerland) and used as
dermal microvascular endothelial cells. HDMECs were plated in
microtiter plates and allowed to grow to confluence over 24 hours.
Sera (100ml) from normal controls and BD patients were diluted 1:50
in Hanks’ balanced salt solution (Sigma, St Louis, MO) with divalent
cations and 1% BSA (Sigma) and added to each well of unfixed
HDMECs, and the plates were incubated for 1 hour at 37 1C.
Peroxidase-conjugated goat anti-human IgA antibody (Invitrogen,
Carlsbad, CA) was diluted 1:1,000 in Hanks’ balanced salt solution
with divalent cations and 1% BSA and added to each well, and the
plates were incubated for 1 hour at 37 1C. Antibody binding was
quantified colorimetrically by adding tetramethylbenzidine (Sigma)
as a substrate, and the plates were read spectrophotometrically at
450 nm on an ELISA reader (Dynatech, Alexandria, VA).
Western blotting using HDMEC antigen
HDMEC antigen in EDTA/BSA was dissolved in buffer (1 mM
phenylmethylsulfonyl fluoride, 1 mM EDTA, and 1% Triton X-100)
on ice for 30 minutes. Samples were then loaded into the wells of a
12% polyacrylamide gel. The separated gel was transferred to a
nitrocellulose membrane, washed with 0.05% phosphate-buffered
saline with Tween-20 (PBST), and incubated overnight at 4 1C in
blocking buffer. After a second overnight incubation at 4 1C with
gentle agitation in sera from 5 normal controls and 10 BD patients,
diluted 1:500 with PBS, the membrane was washed six times with
PBST and then incubated with peroxidase-conjugated goat anti-
human IgA diluted 1:10,000 for 1 hour.
Immunoprecipitation
HDMECs were lysed in a RIPA buffer. Total cell extract (500 mg) was
incubated with mixed sera (equal volumes from 10 BD patients) for
16 hours. Protein G-Sepharose (Sigma) was preincubated with 5mg
of goat anti-human IgA. Thereafter, PBS buffer–washed protein
G-Sepharose beads were added and mixed overnight at 4 1C. The
immunoprecipitates were suspended in a sample buffer containing
100 mM dithiothreitol and 4 M urea and resolved by 10% SDS-PAGE.
In-gel digestion and LC-MALDI-TOF/TOF analysis
The excised gel pieces were destained by reduction with a solution
of 30 mM potassium ferricyanide/100 mM sodium thiosulfate and then
washed with water. The gel pieces were incubated with 0.2 M
NH4HCO3 for 20 minutes, dehydrated, and shrunk by 100%
acetonitrile twice, and then dried by vacuum centrifugation.
For in-gel digestion with trypsin, the gel pieces were rehydrated
in the digestion buffer containing 0.05 M NH4HCO3 and 10 ng ml
–1 of
modified porcine trypsin (Promega, Madison, WI) at 4 1C for
30–45 minutes. The excess supernatant was removed and the gel
pieces were covered with 30 ml of the 0.05 M NH4HCO3 buffer.
Digestion was performed overnight at 37 1C. After in-gel tryptic
digestion, tryptic peptides were extracted from the gel particles.
The LC-MALDI-TOF/TOF experiment was carried out using a
capillary LC equipped with a Q-TOF Ultima mass spectrometer
(Waters, Milford, MA). Peptide ions were detected in the data-
dependent analysis mode with an MS precursor scan
(200–1,800 AMU), followed by three data-dependent MS/MS scans.
For data analysis, the collected raw MS/MS spectra were analyzed
with the Mascot Search program (http://www.matrixscience.com/)
using both the Swiss-Prot and NCBI human databases (Perkins et al.,
1999). The mass tolerance used for acceptance was 1.0 AMU for both
molar masses of the precursor peptide and peptide fragment ions. For
screening the search data, only peptides yielding larger than a
minimum Mascot score of 30 were accepted as having extensive
homology.
Bacterial expression and purification
Human hnRNP-A2/B1, streptococcal hsp-65, and a-Synuclein were
each overexpressed in E. coli BL21, followed by purification of
recombinant proteins to apparent homogeneity using Ni-NTA resin,
according to the manufacturer’s instructions (Sigma). Protein
concentrations were determined with the BCA assay kit (Pierce,
Rockford, IL) according to the manufacturer’s recommendations,
using BSA as a protein standard. Purified recombinant human
hnRNP-A2/B1 was confirmed by western blotting using mouse
anti-human hnRNP-A2/B1 monoclonal antibody (ab6102; Abcam,
Cambridge, UK). Purified recombinant streptococcal hsp-65 and
a-Synuclein were confirmed by DNA sequencing. Protein samples
were stored at 30 1C until use.
Western blotting using recombinant human hnRNP-A2/B1
Purified recombinant human hnRNP-A2/B1 (1mg) was suspended in
sample buffer. The samples were loaded onto a 12% polyacrylamide
gel and subjected to electrophoresis at 100 V. The membrane was
incubated with gentle agitation overnight at 4 1C with serum samples
from normal controls or patients with BD, SLE, RA, TA, and IgAN,
diluted 1:500 with a primary antibody dilution buffer. The
membrane was washed six times with PBST and incubated at room
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temperature for 1 hour with peroxidase-conjugated goat anti-human
IgA antibody diluted 1:10,000 in blocking buffer and visualized by
enhanced chemiluminescence. Western blotting using recombinant
human a-Synuclein was performed as a recombinant protein control
under the identical conditions. For the cross-immunoabsorption test,
western blotting using recombinant human hnRNP-A2/B1 was
delivered using BD patients’ sera preincubated with 0.5 and 2mg
of recombinant streptococcal hsp-65, as well as 0.5 and 2 mg of
recombinant human a-Synuclein.
ELISA using recombinant proteins
Recombinant human hnRNP-A2/B1, streptococcal hsp-65, and
a-Synuclein were coated overnight at 4 1C with 100ml of each anti-
gen solution in carbonate-bicarbonate buffer containing 2 mg ml–1 of
proteins at pH 9.6. Sera (100 ml) from 30 healthy controls, 30 BD
patients, 30 SLE patients, 30 RA patients, 30 TA patients, and 30
IgAN patients were diluted 1:500 in Hanks’ balanced salt solution
with divalent cations and 1% BSA, and added to each well of
recombinant human hnRNP-A2/B1, streptococcal hsp-65, and
human a-Synuclein, respectively. Peroxidase-conjugated goat anti-
human IgA antibody was diluted 1:10,000 in Hanks’ balanced
salt solution with divalent cations and 1% BSA, and added to each
well of recombinant human hnRNP-A2/B1, streptococcal hsp-65,
and human a-Synuclein.
Statistical analysis
One-way analyses of variance with Bonferroni’s post hoc test,
Spearman’s rank correlation coefficients, w2 tests, Fisher’s exact tests,
and Student’s t-tests were performed. Differences were considered
statistically significant when the P-value was o0.05.
Additional Materials and Methods can be found in Supplemen-
tary Material online.
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